IL18 and diabetic retinopathy: By inhibiting the activation of NLRP3, ASC, caspase-1, and NF-κB to reduce the production of IL-1β and IL-18, propelling RvD1 to be expected an effective means to alleviate the progression of diabetic retinopathy (Yin et al., 2017).